MYTHBUSTER: Reporting Q4087 for IVIG? Not Anymore

Why This Topic Matters

The piece matters because it highlights a payer-driven code update that affects claim acceptance for immune globulin services. It helps practices recognize that older reporting habits may no longer align with current Medicare processing for these services.

Article Sections

1. MLN Matters update on IVIG billing changes

   Introduces the Medicare guidance update and explains that immune globulin billing has changed from prior reporting practices. It frames the article around HCPCS updates and claim-processing implications.

2. Updated HCPCS product codes for immune globulin

   Summarizes the revised product-specific coding approach for immune globulin injections. The section focuses on the categories of HCPCS changes and the products referenced in the update.

3. Pre-administration service reporting

   Describes the Medicare-recognized service associated with obtaining and preparing the immune globulin product. It explains the general billing context for this service alongside the drug code.

4. Administration coding guidance

   Covers the infusion administration reporting framework for these services and notes that the article contrasts the relevant infusion codes with other administration coding categories. It also includes a short example illustrating the overall claim components.